Top 4 Clinical Trial Trends for 2023Posted on 01/18/23
Top 4 Clinical Trial Trends for 2023
As we enter a new year, we cannot help but wonder what comes next for clinical trials and product development. What will be the next big thing? What new research will be uncovered in the following months and how? And maybe most importantly, how will the pharmaceutical industry be impacted by it all?
Here are the top four clinical trial trends to keep an eye out for in 2023.
DEI (Diversity, Equity and Inclusion)
The FDA released guidance for sponsors to develop a Race and Ethnicity Diversity Plan. This allows those who may not have had access to or knowledge of trials a chance to be a part of them. The challenge, however, is determining how to expand the reach of the trial. Many sites are looking to use decentralized trial tactics and digitalize as much as possible.
Find out more about Clinical Trial Diversity here.
RPM and Digitalization
In its simplest form, RPM involves connected electronic tools to record personal health and medical data in one location reviewed by a provider at a different location. We believe there will be an increase in use of smart watches, digital blood pressure monitors, gait devices, and more throughout 2023 trials. Although some researchers may continue to be skeptical of accuracy in these devices.
Further information on RPM can be found here.
Decentralized Clinical Trials (DCTs) are not new. The product development space has been reaching for DCTs for years, and as we saw with COVID-19, DCTs accelerated. Now in 2023 we believe there will be even more decentralized trials. This is part of a domino effect from the push to diversify patients in trials.
Learn more about DCTs and their impact on patients here.
Partnerships and Outsourcing
More companies are turning to partnerships and trusted experts in clinical trials to support their needs – bridging the gap in expertise, leveraging networks in drug sourcing, and cutting costs.
Finding a partner in clinical trial supply who understands the complexities and nuances you face is difficult. When the right partner is found, it can relieve companies looking to utilize their clinical trial supply to gain insights and have experts achieve what they thought was not possible. We know the difficulties involved in clinical trials and are built upon assisting drug developers in achieving their goals, no matter what stage of development they are in.
Leveraging a partner like Myonex allows you to combat the ever-changing landscape of clinical trials in 2023.